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CHAPTER I 
 
HEMOZOIN IN SCHISTOSOMIASIS 
 
Introduction 
Considered one among a number of neglected tropical diseases, schistosomiasis 
continues to be one of the most widespread parasitic infections and has considerable 
economic and public health consequences.
1, 2
  Among parasitic diseases, schistosomiasis 
is second only to malaria when ranked by the number of people it kills or chronically 
disables and the disruption of socioeconomic development.
2
  Figure 1 shows the 
distribution of schistosomiasis infection.  Schistosomiasis is typically seen in areas where 
clean water is available in short supply, as schistosome contamination requires human 
and molluskan hosts to regularly occupy the same body of water as in Figure 2.  The 
Figure 1.  Distribution of Schistosomiasis infection.  Schistosomiasis is ranked 
second only to malaria in parasitic infection and presents over 200 million cases a 
year with over 200,000 deaths.
3
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disease costs an estimated annual loss of about 3.1 million disability adjusted life years.
4
  
The highest occurrence and infection intensities are seen in school age children, 
adolescents and young adults, resulting in lowered school perfomance.
5
  Schistosomiasis 
infections undermine social and economic development in strongly afflicted areas. 
 
Lifecycle of Schistosoma mansoni 
The etiological agent of schistosomiasis, Schistosoma spp., maintains a digenetic 
life cycle.  The two hosts, a mammalian species and aquatic mollusks, Biomphalaria 
glabrata for S. mansoni, must regularly occupy the same bodies of water.  Miracidia 
search for snails in fresh water and enter the snail through the head or the foot, migrating 
Figure 2.  Human exposure to schistosome-infected water at Lake Taabo, Cote 
d’Ivoire.4   
3 
 
to the digestive gland to multiply and develop into cercariae, a process that takes four to 
six weeks.  Cercariae then migrate to the snail’s mantle and are shed into fresh water 
where they seek out mammalian hosts.  B. glabrata can shed up to 3000 mature cercariae 
daily from day 28 post exposure for the remainder of the snail’s life, and these are viable 
Figure 3. Life cycle of Schistosoma spp.  S. mansoni utilizes the mollusk 
Biomphalaria glabrata; S. haematobium uses Bulinus truncatus truncatus; 
and Oncomelania hupensis hupensis and O. hupensis quadrasi serve as the 
molluskan host for S. japonicum.  
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in fresh water for up to 48 hours.  Cercariae enter their mammalian host through 
unbroken skin, losing their tails and becoming schistosomulae.  The process of host 
penetration is directed by chemokines and skin surface lipids.
6, 7
  Schistosomulae then 
migrate through the vascular system to mature and take up residence in the hepatic portal 
vein.  Mature blood flukes of Schistosoma spp. catabolize host hemoglobin from red 
blood cells at a rate of about 330,000 red blood cells (RBC) per hour for female worms 
and 39,000 RBC per hour for males in order to obtain required amino acids.
8
  Free heme 
released in this process is biomineralized to  hemozoin (HZ).  The stored HZ is visible in 
the guts of the adult worms.  Excess HZ is regurgitated into the host vasculature and 
engulfed by professional phagocytes.  The adult worms pair and lay eggs, up to 300 day 
per female,
9, 10
 and these are either deposited in tissue or shed in feces.  About half of the 
eggs released become lodged in tissue and are responsible for damage done to those 
tissues.  Eggs that are excreted in fresh water release miracidia which then seek out B. 
glabrata to perpetuate the parasites’ life cycle.  This process is depicted in Figure 3. 
 
Hemoglobin Catabolism and Hemozoin Formation 
Hematophagous organisms, which catabolize hemoglobin for amino acids, must 
evolve a mechanism to contain or detoxify free heme released during this process, as free 
heme can lead to oxidative stress.
11, 12
  The malarial Plasmodium spp., kissing bugs of the 
species Rhodnius prolixus, and blood flukes of the genus Schistosoma employ a similar 
solution to this challenge.  These organisms sequester free heme, ferriprotoporphyrin IX 
(Fe(III)PPIX), into a biomineral consisting of centrosymmetric dimers.  These dimers 
form through reciprocal coordination of the propionate side chain of the individual 
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Fe(III)PPIX’s to the Fe(III) center of its partner.  These dimers then hydrogen bond to 
other dimers of the same through the unionized propionic acid groups to form a crystal 
with well defined faces, as shown in Figure 4.
13
  This crystalline pigment, observed 
before the etiological protozoan of malaria itself, came to be known as hemozoin (HZ).  
Although HZ has been shown to have negative effects both in vitro and in cellular 
systems,
14-23
 HZ has been shown to be less toxic to these parasites than free heme due to 
the reduced availability of the core of the crystal for participation in oxidation-reduction 
reactioncs.
24
  The formation of HZ is therefore a viable method for heme detoxification. 
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Figure 4. Three stacked dimers of HZ, hydrogen bound through 
unionized propionic acid side chains.  Formation of dimers occurs 
through Fe–O bonds.  
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Structure of Hemozoin 
 The malarial pigment HZ was erroneously described as a hemoprotein until a 
study by Fitch and Kanjananggulpan in which it was shown by extensive purification to 
consist of only Fe(III)PPIX.
25
  This was confirmed by Slater et al. in 1991.  Using 
UV/visible spectroscopy, infrared spectroscopy, and extended x-ray absorption fine 
structure, Slater et al. were able to show that the structure of HZ is identical to that of β-
hematin (BH), a synthetic product made from precipitation of Fe(III)PPIX in aqueous 
solution with acetic acid.
26
  This description led to the proposal of a heme polymer, 
which in turn directed the futile search for a heme polymerase.  Six years later, Bohle et 
al. provided further evidence that BH is indeed identical to HZ and suggested a structure 
of antiparallel polymer chains.
27
  Finally in 2000, Pagola et al. were able to show that HZ 
and BH are not polymers, but dimers bound through reciprocal iron-carboxylate linkages 
of the propionate side chains of each Fe(III)PPIX.
13
  
 
β-Hematin 
As native hemozoin (HZ) is available in exceptionally limited quantities and only 
at a cost of organism life or health, synthetic hemozoin or β-hematin, is utilized in many 
studies.  Crude HZ is defined as pigment that is isolated from parasitized erythrocytes 
and, although it may be washed to remove cellular debris, the lipid coat adsorbed onto the 
hydrophobic porphyrin plane is left intact; whereas purified hemozoin is that which has 
had the lipid coat removed during more intense washing with a detergent or organic 
solvent.
26, 28, 29
  Finally, synthetic hemozoin, BH is synthesized in vitro from hemin 
chloride and is devoid of all biologically derived components.
22, 30
  Characterization of 
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BH has demonstrated that the material is chemically, spectroscopically, and 
crystallographically identical to HZ.
13, 25-27
     
 
Immune Response to Schistosomiasis 
While the contribution of HZ to pathology in malaria has proposed,
14-17, 20, 22, 31-33
 
its role in schistosomiasis has been largely overlooked.    Studies of pathology in 
schistosomiasis have concentrated mostly on egg deposition, granuloma formation, and 
adaptive immune response.  The role of HZ in schistosomiasis pathology has been 
minimally examined.  It is the goal of this research to show that HZ has pathological 
implications in schistosomal infection.    
 HZ has been shown in malaria to act as a potent immunomodulatory agent.  When 
HZ is phagocytosed by monocytes, these cells become impaired, their ability to 
accomplish subsequent phagocytic challenges hindered.
14, 15, 20, 34
  Phagocytes also have 
difficulty breaking down HZ; indeed, it can be detected in tissue for at least nine months 
post parasite clearance.
15, 35
  HZ fed monocytes remain viable cells, but become unable to 
generate oxidative burst with appropriate stimulation
14, 15
 and show decreased aptitude for 
killing ingested microbes.
36
  These cells produce less reactive oxygen and nitrogen 
species, whose purpose is to attack invading particles.
15, 22, 23, 37
  HZ has been shown to 
reduce function of protein kinase C in human monocytes.
16, 17, 32
  It has also been shown 
to affect MHC class II expression
16
 and damage dendritic cell function.
38, 39
  The presence 
of HZ has been shown to coincide with products of lipid oxidation.
17, 19, 40
   
 One of the most examined sources of pathology in schistosomiasis is granuloma 
formation.
41
  A mild type 1 helper T cell (Th1) response occurs in response to adult 
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parasite antigens.  However, when oviposition occurs, this is overshadowed by a vigorous 
type 2 helper (Th2) response to egg-derived antigen, resulting in fibrogenesis.
42-44
 The 
chronic form of schistosomiasis is characterized by this persistent inflammatory Th2 type 
reaction leading to granuloma formation.
45, 46
  Granulomas form when eggs laid by adult 
worm pairs get trapped in the microvasculature of the liver.  The embryonic miracidium 
secrete antigens through microscopic pores in the rigid shell of the egg.
47
 These egg-
derived antigens elicit a response from T helper cells (Th).
44, 48
  Phagocytes attack these 
egg depositions. These phagocytes are too small to engulf whole schistosome eggs, and 
usually die trying to attack these eggs.  More phagocytes attend the site of infection, and 
the area around the egg becomes dense with expired immune cells.  These granulomas 
demonstrate inflammation, tissue eosinophilia, and collagen deposition, leading to portal 
hypertension and severe hepatic fibrosis.
41, 42
  Thus, granuloma formation during 
schistosomiasis is generally looked upon as the fundamental pathological event; however, 
it has also been shown that granulomas also function to protect tissues from oxidative 
damage.
49
 
 
Aims 
 It is the goal of this work to demonstrate that hemozoin contributes to the 
pathology of Schistosomiasis through the addition of oxidative stress.  Chapter II 
examines the course of the disease using a murine model.  Chapter III details products 
indicative of oxidative stress that can be made in vitro in the presence of BH or that have 
been found in infected tissues. 
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CHAPTER II 
 
SCHISTOSOMA MANSONI INFECTION IN A MURINE MODEL 
 
Introduction 
 The murine model offers a uniquely qualified examination of the course of 
infection of Schistosomiasis and the immune response that is in many ways reflective of 
these features in human infection.  A murine model has been used previously to 
demonstrate the ability of S. mansoni to induce hepatic oxidative stress via the production 
of reactive oxygen species
50
 and reduce antioxidant defense mechanisms of host tissue.
51
  
Because the course of infection in mice is similar to that in man, it is a useful tool for 
studying the disease.  Thus a time study was embarked upon in order to investigate 
physiological changes and HZ accumulation over the course of infection by S. mansoni. 
Native HZ and its synthetic analogue, β-hematin (BH) are identical in structure, 
but differ dramatically in their availability for collection and surrounding chemical 
environment.  Until recently, the chemical environment of HZ in the parasite and its host 
remained a mystery largely due to the rigors of extraction and limited sample sizes.  
Furthermore, BH does not show the same immunomodulatory effects that native HZ does 
and so, although easier to obtain, is less reliable for HZ host-pathogen studies.
40
  
Schistosomal HZ has previously been isolated from worms perfused from the hepatic 
portal vein of host Swiss Webster mice.
52, 53 
 Methods of isolation of HZ from host liver 
tissue have been described by Pandey et. al.
54
 and from host blood by Deegan and 
Maegraith.
55, 56
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Experimental 
Materials 
 Schistosoma mansoni infected Swiss Webster mice were obtained from the 
Biomedical research instituted in Rockville, MD.  Sodium bicarbonate, monobasic 
sodium phosphate, dibasic sodium phosphate, sodium hydroxide and dimethyl sulfoxide 
(DMSO) were obtained from Fisher.   Sodium dodecyl sulfate and lipopolysaccharide 
(LPS) were obtained from Sigma.  Anhydrous methyl alcohol, and 2,6-lutidine were 
obtained from Acros.  Dulbecco’s phosphate buffered saline (PBS) and RPMI 1640 
media with 2 g/L sodium bicarbonate were obtained from Gibco.  4-hydroxy-2-nonenal 
(HNE) was purchased from Calbiochem.  All chemicals were used as received unless 
otherwise noted. 
 
Time Study 
 A time study was performed in which 60 Swiss Webster mice were infected by 
tail exposure to 150 cercariae.  Mice were euthanized and examined at 4, 5, 6, 7, and 8 
weeks post infection.  Control mice were euthanized and examined at the same time as 
week 8 mice.  The adult schistosomes were perfused from the hepatic portal vein, 
separated by sex and counted.  HZ was later extracted from the worms.  At the time of 
perfusion, host spleens and livers were removed, rinsed, weighed, flash frozen in liquid 
nitrogen and stored at -80°C.  Tissues were homogenized and examined for HZ content.  
Thin tissue sections were stained with hematoxylin and eosin (H&E) and analyzed for 
lipoxidation products. 
11 
 
Isolation, Characterization, and Measuring of HZ from tissues 
 HZ was extracted from the livers and spleens collected in the time study.  Organs 
were individually homogenized using Wheaton 15 mL glass homogenizers.  The 
homogenate was rinsed with deionized water into individual 50 mL polypropylene tubes 
and centrifuged at 1000 x g for 1 minute.  The supernatant was removed and centrifuged 
at 3900 x g for 2 hours.  The supernatant was discarded and the pellet rinsed in 1 mL of 
150 mM phosphate buffer, pH 7.4 (28.5 mL of 0.2 M monobasic sodium phosphate, 
NaH2PO4•H2O, with 121.5 mL of 0.2 M dibasic sodium phosphate, Na2H2PO4•7H2O, 
diluted to 200 mL).  The pellet was vortexed slightly and light colored tissue was 
removed along with phosphate buffer.  500 μL of 150 mM phosphate buffer and 500 μL 
of ethyl acetate were added to the remaining dark pellet.  The pellet was vortexed, 
centrifuged at 1000 x g for 1 min, and the supernatant removed.  This last step was 
repeated until supernatant appeared clear.  The alleged HZ pellet was dried under 
nitrogen gas and confirmed via UV/visible spectroscopy (UV/vis), Fourier-transform 
infrared spectroscopy (FT-IR), powder x-ray diffraction (XRD) and scanning electron 
microscopy (SEM). 
 Dried HZ from host organs was ground using mortar and pestle, mixed with dry 
KBr and pelleted using a hydraulic press for FT-IR.  Dried HZ from host organs was 
ground using mortar and pestle and analyzed by XRD on a Scintag X1 h/h automated 
powder diffractometer with a copper target, a Peltier-cooled solid-state detector and a 
zero-background silica (510) sample support. in a 12 hour run.  SEM samples were 
dissolved in ethanol, dried to SEM mounts, and gold-sputtered for 200 seconds before 
imaging on a Hitachi S-4200 SEM.   
12 
 
   
HZ collected from the time study was quantified using a method based on that 
described by Sullivan.
57
  HZ was scraped from 50 mL polypropylene tube into a mortar 
and pestle where it was ground to a fine powder.  The sample was then rinsed back into 
the same polypropylene tube with 10 mL of 150 mM phosphate buffer, pH 7.4.  The 
mixture was then sonicated and vortexed immediately before pipetting 500 μL of solution 
into 500 μL of 20 mM NaOH, 2%SDS to dissolve HZ into individual heme units.  The 
mixture was allowed to sit for 1 hour before the absorbance was read at λ = 400 nm.  The 
resultant concentration of heme was determined using Beer’s law and ε = 10,000 for 
heme. This was repeated for 5 livers and spleens from hosts for weeks 4 through 8 of the 
time study.   
 
Results and Discussion 
Time study of course of infection in murine model 
 Over the eight weeks encompassed by the time study, the livers of infected mice 
were shown to more than double in size, increasing from 5% of body weight for 
uninfected mice to more than 15% of total body weight by week 8 of infection.  The size 
of the spleen increased in a similar manner from 0.4% to about 3% of the total body 
weight.  The overall body weight of the infected mice was the same or lower than control 
mice at eight weeks, indicating that the increased weight of the inflamed organs was 
accompanied by decreased overall mouse body weight.  Worm recovery via perfusion of 
the hepatic portal vein averaged about 22% of cercarial infection, with a peak worm 
recovery seen at week six. 
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Isolation and characterization of hemozoin from host tissues 
 Structurally, chemically, and spectroscopically, the HZ isolated from murine 
tissues appears identical to all previously identified forms, including BH and malarial 
pigment.  The UV/vis spectrum of liver isolated HZ in Figure 6 shows the characteristic 
Soret band at 400 nm for heme.  Average HZ content per organ per week is compared in 
Figure 7.  The FT-IR spectrum, depicted in Figure 8, showed stretches at 1659 cm
-1 
and 
1235 cm
-1
; the accepted values are 1664 and 1211 cm
-1
 for C=O and C—O, respectively.  
In Figure 8, the liver homogenate hemozoin is shown in blue, BH is shown in red, and 
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Figure 5.  Comparison of S. mansoni infected hosts and host tissues by weight over course 
of infection.   
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HZ isolated from homogenized Schistosomes is shown in black.  The expected peaks are 
present; however, the percent transmittance is much lower in the native hemozoin sample 
due to a possible lipid coating. 
X-ray diffraction of tissue originated HZ showed characteristic 2θ peaks at 7º, 
21º, and 24º.  Figure 9 shows the XRD pattern of liver HZ in blue, along with hemin in 
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Figure 6. UV/vis spectrum of HZ isolated 
from S. mansoni infected murine liver. 
Figure 7.  Comparison of HZ accumulation 
in murine host tissues. 
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Figure 8.  FT-IR spectrum of HZ isolated 
from S. mansoni in black, from infected 
liver tissue in blue, and from BH in red. 
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Figure 9.  XRD spectrum of BH in red, 
liver isolated HZ in blue and hemin in 
green. 
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green and BH in red.  The hemin, which is the main substrate for the synthetic BH, shows 
a peak at 23º that is noticeably absent in the synthetic product and the tissue HZ.  The 
expected peaks for hemozoin are noted in the liver hemozoin pattern; however, additional 
peaks are also observed as well as an increase in background, likely due to anisotropy in 
the native sample as compared to the more crystalline synthetic samples. 
SEM images of HZ were bright due to remaining sample charge. In general, the 
sample displayed a large size distribution and heterogeneous morphology, as would be 
expected from a native hemozoin sample formed along a lipidous template and organized 
by cellular processing.
52, 58
  Figure 10 shows SEM images of hemozoin collected from 
Figure 10.  SEM images of HZ isolated from S. mansoni infected murine livers.  Images 
shown at 8.57 μm, 3.75μm, 749 nm, and 500 nm. 
16 
 
host tissue at 8.57 μm, 3.75 μm, 7.49 nm, and 667 nm, respectively.  On the nanometer 
scale, rods of crystalline hemozoin can be observed.  Similar rods were noted previously 
in hemozoin from the malarial parasite Plasmodium falciparum.
59
   
 
Conclusions 
 A new method was developed for the isolation of HZ from murine host tissue.  
Previous methods for isolation of HZ from host tissues lacked the simplicity of this new 
method.
54
  Yields of HZ from host tissue over the course of an eight week infection were 
compared, and a steady increase of HZ in tissues was shown, although relative parasite 
burdens remained relatively constant.  This indicates that HZ remains in the tissue rather 
than being discarded by the host immune system.  This has been shown previously in 
malaria.
15, 35
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CHAPTER III 
 
DEMONSTRATION OF OXIDATIVE STRESS 
 
Introduction 
 Heme-based compounds are significant sources of non-enzymatic lipid 
oxidation.
60
  The lipoxidation products generated have the ability to modify immune 
responses.  Hemozoin has been shown to modify the biological response of phagocytes 
that engulf it.
14, 15, 20, 34
  Furthermore, the presence of HZ has been shown to coincide with 
biologically active products of lipid oxidation.
17, 19, 40
  In Chapter III, more evidence of 
HZ as a generator of immunomodulatory oxidation products is offered. 
 
Experimental 
Materials 
 Sodium bicarbonate, monobasic sodium phosphate, dibasic sodium phosphate, 
dimethyl sulfoxide (DMSO), 2-propanol, and acetic acid were all obtained from Fisher.  
N-(1-naphyl)ethylenediamine (NED), sulfaniliamide, hemin chloride (bovine), and 
lipopolysaccharide (LPS) were obtained from Sigma.  Anhydrous methyl alcohol, and 
2,6-lutidine were obtained from Acros.  Arachidonic acid was obtained from Nu-Chek 
Prep, Inc.  Dulbecco’s phosphate buffered saline (PBS) and RPMI 1640 media with 2 g/L 
sodium bicarbonate were obtained from Gibco.  RPMI was supplemented with 10% fetal 
bovine serum (FBS, Atlanta Biologicals) and 100 μg/mL penicillin-streptomycin (P/S, 
Cellgro Media Tech) before use.  4-hydroxy-2-nonenal (HNE) was purchased from 
18 
 
Calbiochem.  HNE immunohistochemical staining reagents were purchased from R&D 
Systems.  Packed red blood cells (RBC) were a donation from the VUMC Blood Bank.  
All chemicals were used as received unless otherwise noted. 
 
β-Hematin (BH) synthesis and characterization 
BH was synthesiszed via a dehdrohalgenation reacton as previously described.
30, 
40
 Purified hemin chloride (Fluka, 3.0 g) was dissolved in 5 mL of 2,6-lutidine with 
stirring under an inert atmosphere.  Forty mL of 1:1 dimethylsulfoxide (DMSO) 
/anhydrous methanol was added to the flask with stirring.  The flask was sealed, covered 
in foil, and left undisturbed for ninety days.  The solution was then removed from the 
glove box and crude BH was collected via vacuum filtration with a 0.45 μm filter.  BH 
was washed with methanol (MeOH), DMSO 0.1 M sodium bicarbonate (NaHCO3, pH 
9.0), and deionized water.  BH purity was monitored with UV-visible spectroscopy 
established by baseline absorption of the Soret band for heme in the supernatant of the 
washes.  BH was then dried for 48 hours at 150˚C.  Product was confirmed by powder X-
ray diffraction (XRD), Fourier Transform Infrared Spectroscopy (FT-IR), and scanning 
electron microscopy (SEM).  XRD studies were performed with a Scintag X1 h/h 
automated powder diffractometer with a copper target, a Peltier-cooled solid-state 
detector and a zero-background silica (510) sample support.  XRD study parameters were 
as follows:  0.02 step size, 25 second preset time, scan range 4 to 35˚ 2θ.  FT-IR 
spectroscopy was performed on an ATI Mattson Genesis Series FT-IR spectrophotometer 
using KBr pellets prepared with dried BH.  A Hitachi S4200 SEM was used to image BH.  
BH was suspended in ethanol, sonicated, applied to a polished aluminum specimen 
19 
 
mount, and dried at 25˚ C overnight.  The sample was sputter-coated with gold for 20 
seconds prior to imaging. 
 
BH-mediated isoketal (IsoK) formation 
 Arachidonic acid (AA, 10 mM) was oxidized in 1.25 mL of 100 mM phosphate 
buffer (chelexed, pH 7.4) in the presence of BH at concentrations of 0.48, 0.36, 0.24, 0.12 
and 0.00 mM.  250 μL of ethanol was added to the reaction mixture to aid in solublizing 
AA.  The reaction was stirred for two hours at room temperature before 100 μM 
pyridoxamine dihydrochloride was added.  The reaction continued to stir at room 
temperature for two more hours.  Reaction mixtures were extracted with diethyl ether.  
The organic layers of each sample were combined and dried down.  The samples were 
then redisovled in 50μL of acetonitrile. 
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
 LC-MS/MS analysis of isoketal products was performed using a ThermoFinnigan 
TSQ Quantum triple quadruple equipped with a ThermoFinnigan Surveyor LC.  Products 
were separated on a Magic Bullet C18AQ micro column (3 μm, 100 Å, Michrom 
BioResources, Auburn, CA) with the gradient programmed from 100% solvent A (5 mM 
ammonium acetate with 0.1% acetic acid) to 100% solvent B (acetonitrile/methanol 95:5) 
from 0.5 minutes to 3 minutes and then continuing at 100% B for an additional 1.5 
minutes.  The column was then equilibrated to 100% A for 2.5 minutes.  The flow rate 
was set to 190 μL/min and the injection volume was 5 μL.  The mass spectrometer was 
operated in positive ion mode with a spray voltage of 3.7 kV, a capillary temperature of 
20 
 
210˚C, a capillary voltage of 35 V,  source CID of 5 V, and collision energy of 30 eV.  
Product scan spectra of the isoketal-pyridoxamine-lactam adduct ([M+H
+
]) m/z 501 were 
acquired from 50 m/z to 520 m/z.  Selective reaction monitoring (SRM) was used to 
confirm m/z 501→m/z 152 and m/z 332 transitions, calculated as -17 Da from the parent 
isoketal-pyridoxamine-lactam mass.  Data was acquired and analyzed using Thermo-
Finnigan Xcalibur software. 
 
Isoprostanes from BH-mediated ghost membrane peroxidation 
RBC ghosts were prepared from expired whole blood obtained from the 
Vanderbilt Medical Center Blood Bank.  Whole blood was kept at 4˚C until use and 
mixed inside the bag before use.  A 22 gauge needle fitted to a disposable syringe was 
used to draw 3 mL of whole blood which was then expelled into a 15 mL polypropylene 
centrifuge tube.  11 mL of phosphate buffered saline (PBS) was added and the tube was 
gently inverted to mix.  The solution was then centrifuged on a Beckman Coulter Allegra 
x-22R centrifuge at 1000 xg for 10 minutes in the Beckman SX4250 swing bucket rotor.  
The supernatant was discarded in bleach, and this wash was repeated until the supernatant 
appeared clear.  The RBCs were then lysed by dissolving the pellet in 0˚C 5 mM sodium 
phosphate buffer in 50 mL polypropylene tubes and vortexing.  The solution was then 
centrifuged at 10,000 xg using the fixed angle Beckman C0650 rotor.  The supernatant 
was discarded, and this wash was repeated until no trace of red could be seen in the 
membrane pellet.  The pellet was then dissolved in a minimum amount of PBS and 
aliquoted to be stored at -80˚C.  A Biorad assay was used to determine the protein content 
of the final solution.  Briefly, standards were made with bovine serum albumin from 1.5 
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mg/mL to 0.2 mg/mL.  5 μL of standards and samples were pippetted into a clean, dry 96 
well plate.  25 μL of Bio-rad reagent A, an alkaline copper tartrate solution, were added 
to each sample followed by 200 μL of reagent B, a dilute 1,2-naphthoquinone-4-sulfonate 
solution.  The plate was allowed to sit for 15 minutes, after which the absorbance was 
read at 750 nm.  RBC ghosts were used for reactions at protein concentrations of 1 
mg/mL, as determined by the Biorad Protein assay. 
RBC ghosts were stirred in the presence of oxygen with ethanol, 10 mM BH, 
arachidonic acid, and phosphate buffer quantity sufficient to 800 μL for four hours before 
the reaction was stopped with 50 μL of 1 M HCl. The samples were then immediately 
delivered to the lab of L. Jackson Roberts for isoprostane analysis.  
 
Stains of S. mansoni infected murine tissues 
 Livers and spleens from the time study mentioned above were affixed to glass 
slides by the Vanderbilt University Immunohistochemistry core.  Thin sections were 
sliced at a thickness of 5 μm.  Two stains were made, hematoxylin and eosin (H&E) 
stains were used to examine cell morphology. 4-hydroxy-2-nonenal (HNE) stains were 
used to verify the presence of elevated levels of HNE in infected tissue. Staining for 4-
hydroxynonenal was done using an anti-HNE monoclonal antibody from R & D Systems 
and a R & D Systems cell and tissue staining kit.  The sample was covered with 2 drops 
of a 3% peroxide solution to block peroxidase.  The reagent did not readily sit on the 
paraffin sealed tissue section and so was held in place with a glass cover slide.  The 
sample sat in peroxidase blocking reagent for 5 minutes followed by a 5 minute wash 
with phosphate buffered saline solution (PBS).  The slide was then incubated with 2 
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drops of serum blocking reagent for 15 minutes.  The slide was drained, but not rinsed, 
and then incubated with 2 drops of an avidin solution containing 0.1% sodium azide.  The 
slide was then rinsed with sterile PBS, drained and excess buffer blotted from the sample.  
The slide was then incubated with 2 drops of a biotin blocking reagent for 15 minutes at 
room temperature.  The slide was then rinsed with buffer and incubated at 37°C with 25 
μL of the primary antibody, monoclonal anti-4-hydroxynonenal, at 25 μg/mL for 1 hour.  
The sample was rinsed with buffer 3 times for 15 minutes each wash.  The slide was then 
incubated with 2 drops of biotinylated secondary antibody for 60 minutes at 37°C.  
Following another 3 fifteen minute washes with PBS, the slide was incubated with 2 
drops of a high sensitivity streptavidin horse radish peroxidase conjugate for 30 minutes 
at 37°C.  After another 3 cycle PBS wash, 2 minute each wash, the slide was then blotted 
to remove excess buffer.  The slide was then treated with 25 μL of a chromogen, a 2% 3-
amino-9-ethylcarbazole solution mixed with a 0.1% peroxide solution to activate.  The 
slide was incubated with this chromogen for 1 hour and 20 minutes at 37°C.  This process 
was repeated for livers and spleens collected from the time study for weeks 4, 5, 6, 7, and 
8 post infection as well as controls.  Images were obtained on an Olympus BH2-RFCA 
light microscope coupled with and Olympus DP70 camera.  
 
Results and Discussion 
 This thesis seeks to implement hemozoin as a source of oxidative stress in 
schistosomiasis.  To that effect, the ability of HZ to generate oxidative stress markers in 
vitro was examined.  Also the detection of an oxidative stress marker in host tissues 
coinciding with HZ tissue deposits is disclosed. 
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Proposed mechanisms of BH-mediated lipid peroxidation 
 Mechanisms associated with non-enzymatic arachidonic acid peroxidation result 
in primary hydroperoxide species which differ by the location of that group along the 
carbon backbone.  These are known as n-hydroperoxyeicosatetraenonic acids (n-
HPETEs), where the number replacing n identifies the position of the hydroperoxide 
moiety. These primary peroxidation products are generally short lived and lead to many 
secondary peroxidation products, including notably isoprostanes, isoketals, and 4-
hydroxynonenal, along with many others.    
 
BH-mediated isoketal (IsoK) formation 
 IsoKs are 1,4-dicarbonyl compounds that are known markers of oxidative stress.
61
  
They readily adduct to proteins at lysine residues, resulting in pyrrole, lactam, and 
hydroxylactam adducts.  Due to their labile nature, isoKs are short-lived as products.  To 
that effect, the scavenger molecule pyridoxamine was added to these reactions for the 
purpose of detection via LC-MS/MS.  Pyridoxamine has been shown to react quickly and 
selectively with isoKs.
62
  The isoK-pyridoxamine-lactam adduct was observed as a parent 
501 m/z with transitions to 152 m/z and 332 m/z products.  
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Not only was BH able to induce isoK production from arachidonic acid, but also 
in reactions in which arachidonic acid was stirred in the presence of oxygen with 
increasing concentrations of BH, relative peak areas were observed to increase with 
increasing BH concentration, as shown in Figure 11.  Attempts to quantitatively study 
isoK are documented in Appendix D.   
 
BH-mediated production of isoprostanes (isoP) and isofurans (isoF) 
 Isoprostanes and isofurans have also been shown as indicators of oxidative stress, 
in malaria and other diseases.
63
  In continuing the search for markers of oxidative stress 
able to be generated by the presence of BH, reactions were arranged in which BH was 
allowed to stir in the presence of oxygen with RBC membranes and arachidonic acid.  
Figure 11.  IsoK-pyridoxamine-lactam adduct was detected via LC-MS/MS 
in extracts from reactions of arachidonic acid and BH, using pyridoxamine 
as a scavenger.  This chart compares the relative amounts detected in 
reactions with increasing concentrations of BH. 
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These reactions were stopped and taken to Brooke Gliga in L. Jackson Roberts lab for 
extraction and determination of isoP and isoF levels.  Figure 12 shows her reported levels 
of isoP and isoF.   
 
Signs of stress in host tissues 
 Hematoxylin and eosin stains of stains of S. mansoni infected mouse liver and 
spleen thin sections from the time study described above were examined.  In these stains, 
fibrotic granulomas which surrounded the eggs of the parasites were clearly observed in 
the livers of later weeks of the time study as opposed to controls.  Also, in spleen tissue, 
by week eight post infection, megakaryocytes were observed.  Megakaryocytes in the 
spleen, indicative of extramedullary hematopoiesis, are seen most often as a result of 
pathologic process and are a sign of stress in an organism.
64
  The H & E stains are shown 
Figure 12.  Isoprostane and Isofuran isolated from BH reactions 
with arachidonic acid and RBC ghosts.   
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alongside HNE immunohistochemical stains for comparison in Figure 13 for livers and 
Figure 14 for spleens. 
 
Figure 13.  Anti-HNE (1) and H&E (2) stains of uninfected (A) murine livers and 
murine livers infected by S. mansoni at 8 weeks (B) and 4 weeks (C) post infection.  
All images shown at 40x magnification. 
A1
1 
A2 
B1 
B2 
C1 
C2 
Figure 14.  Anti-HNE (1) and H&E (2) stains of uninfected (A) murine spleens and 
murine spleens infected by S. mansoni at 8 weeks (B) and 4 weeks (C) post infection.  
All images shown at 40x magnification. 
 
A1
1 
A2 
B1 
B2 
C1 
C2 
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Demonstration of HNE in host tissues 
 4-hydroxynoneal (HNE) is a product of non-enzymatic oxidation of cell 
membrane components.
65
  Immunohistochemical stains for 4-hydoxynonenal were 
performed on liver and spleen thin sections from mice infected with S. mansoni.  
Concentrated pink to red staining was seen in certain cells of the liver and spleen tissues.  
The progression of these changes is shown with H&E stains from corresponding weeks 
for comparison.  Figure 13 shows images of liver stains, and Figure 14 shows images of 
spleen stains. 
 
Conclusions 
 Given that morbidity and mortality associated with schistosomiasis is associated 
with liver fibrosis, it should be noted that reactive products of liver peroxidation promote 
fibrogenesis.
66
  The data presented in this chapter entails the production of a few of these 
peroxidation products, namely isoKs and isoPs, in vitro in the presence of BH and shows 
the coinciding of another oxidative stress marker, HNE in proximity to BH deposits in S. 
mansoni infected tissues.    
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APPENDIX A 
ALTERNATIVELY ACTIVATED MACROPHAGES AS A MODEL FOR 
SCHISTOSOME-INDUCED IMMUNE RESPONSE 
 
Alternatively activated macrophages (AAMs) were attempted in murine RAW 
264.7 cells.
67-69
  Activated macrophages are used to study innate immune responses while 
AAMs provide a model to study humoral immunity including repair processes.  
Macrophages, which are a major feature of egg-induced granulomas, possess two 
enzymes, nitric oxide syntase-2 (NOS-2) and arginase-I (Arg-I) that compete for a single 
substrate, L-arginine.  NOS-2 transforms L-arginine to nitric oxide and L-
hydroxyarginine, which can inhibit Arg-I.  This is part of the classical macrophage 
activation pathway, the purpose of which is to destroy pathogens.  Arg-I converts L-
arginine to L-ornithine, which is then converted by ornithine decarboxylase to 
polyamines leading to cell proliferation or by ornithine aminotransferase to proline for 
collagen production.  Cell proliferation and collagen production lead to cell growth and 
connective tissue formation.   This arginase pathway contributes to alternative 
macrophage activation, the purpose of which is to repair tissue.
70
  Whether a macrophage 
is classically activated to up regulate NOS-2 or alternatively activated to up regulate Arg-
I depends on the interplay of Th1 and Th2 type cytokines.    Inflammatory cytokines, 
such as IFN-γ, IL-12 or TNF-α will classically activate macrophages.71  Alternatively 
activated macrophages may be stimulated by IL-4, IL-13, or IL-21.
71, 72
  These pathways 
are depicted in Figure 15.  The presence of the eggs themselves, and the antigens they 
give off, skew the immune reaction to a Th2 type response.
73-76
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 Cells were challenged with the endotoxin lipopolysaccharide (LPS), and nitric 
oxide from the NOS-2 pathway was measured as described by the Griess assay.  To study 
the arginase pathway, cells were plated in 6-well plates at 1x10
6
 cells/well (2 mL of 
5x10
5
 cells/mL RPMI complete media) and incubated overnight.  Media was then 
aspirated and replaced by Dulbecco’s modified eagle medium (DMEM), low glucose, 1 
g/L D-glucose, L-glutamine, 110 mg/L sodium pyruvate, 1% FBS and 1% penicillin, 
streptomycin.  Cells were incubated 20 hours.  Media was aspirated and cells were 
washed twice with phosphate buffered saline (PBS, without Ca
2+
/Mg
2+
).  2 mL DMEM 
without FBS was added again to each well.  Cells were dosed with interleukins 4, 13 and 
21 (IL-4, 13, 21) from 1-40 ng/mL, rotated by hand and incubated 48 hours.  
Measurements of arginase activity were attempted by monitoring the conversion of 
arginine to ornithine by previously described methods.
69
   
Figure 15.  Th1 and Th2 stimulant response pathway in macrophage cells.  
Macrophages have two inducible enzymes for which arginine is the substrate:  
Arginase and NOS-2.  Measurements were attempted of products highlighted 
by square borders.  The top-most Th1 response was induced by LPS challenge 
and the bottom-most Th2 response was induced by ILs-4, 13 and 21. 
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Cells were harvested and lysed with lysis buffer containing 0.5% triton solution 
with trypsin-chymotrypsin inhibitor (0.1 mg/mL), leupeptin (0.05 mg/mL), aprotinin 
(0.05 mg/mL) and pheynylmethonylsulfonyl fluoride (PMSF, 0.2 mM).  After lysis, 25 
µL of 10 mM MnCl2 was added to 25 µL of lysate from each sample.  Samples were 
incubated at 55°C for 20 minutes.  Carbonate buffer (150 µL of 0.1 M) was added to each 
sample.  Half of the samples received 50 µL of 100 mM L-arginine, incubated at 25°C 1 
hour and the reaction stopped with addition of 750 µL of glacial acetic acid.  A 250 µL 
aliquot of 2.5 g/L ninhydrin solution (in ethanol) was added to all samples and brought to 
a boil for 1 hour.  Ornithine production was measured at 560 nm.  Significant distinction 
between control and experimental samples was not established due to interference with 
unreacted substrate.  It was then that arginase activity monitoring was attempted by 
measurement of urea levels in preference to ornithine.  This effort is outlined in appendix 
B.          
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APPENDIX B 
MEASUREMENT OF ARGINASE ACTIVITY VIA UREA PRODUCTION 
 Another measurable product of Arginase activity is urea.  An assay to detect urea 
based on a method by Munder et al. was developed.
77
  Cells were plated and treated as 
described in Appendix A.  In a 96 well plate 25 μL of lysate was treated with 2.5 μL of 
10 mM MnCl2 and heated for 10 minutes at 56˚C to activate enzyme.  25 μL of 0.5 M L-
arginine, pH 9.7, substrate was then added and incubated for 120 minutes.  200 μL 
H2SO4/H3PO4/H2O (1/3/7, v/v/v/) was used to stop the reaction.  10 μL of 9% (w/v) α-
isonitrosopropiophenone in 100% ethanol (ISPF) was added and the solution was heated 
at 95˚C for 30 minutes.  The plate was then read at λ=540 nm.  A calibration curve of 
urea was incorporated in the same plate and treated the same as samples.  Should the 
calibration curve fail on any given plate, the whole plate was discarded.  This assay was 
tried with lysate saved from previous cell experiments described in Appendix A and also 
with the cell treatment repeated.  The urea levels produced from the cell experiments 
appeared to be below the detection limit of the assay. 
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APPENDIX C 
PDTC INHBITION OF NITRIC OXIDE PRODUCTION 
 As an evaluation of ammonium pyrrolidine dithiocarbamate (PDTC) as a tool for 
probing cellular pathways, the ability of the compound to inhibit nitric oxide production 
in murine 264.7 macrophage-like cells was examined.  Cells were plated at 500,000 cells 
per well to a 24 well plate and incubated overnight at 37˚C in 5% CO2.  Media was 
aspirated off, and cells were washed three times with PBS containing Ca
2+
 and Mg
2+
.  
Cells were then treated with 500 μL media containing PDTC with concentrations varied 
from 0 to 100 μM, in duplicate.  HNE was used as a positive control.  Cells were 
incubated for 2 hours, then treated with 10 μL lipopolysaccharide (LPS).  A Griess assay 
was used to assess cell response to challenge.  The results are compared in Figure 16.  
Figure 16. Calibration of PDTC inhibition of NO production in 264.7 cells.   
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APPENDIX D 
QUANTIFICATION OF ISOKETAL FORMATION FROM ARACHIDONIC ACID 
AND BETA HEMATIN REACTION 
 
 In order to quantify isoK-pyridoxamine adduct from reaction of BH with AA, an 
isoK-4-aminomethylpyridine adduct was prepared for use as an internal standard.  4-
Aminomethylpyridine (4-AMPy) is of lower molecular weight than pyridoxamine (PM), 
and so may be distinguished from PM via MS.  4-AMPy also has a strong affinity for 
isoK.  The two compounds are of similar structure and elute from the described HPLC at 
the same time.  4-AMPy-isoK standard was prepared and cleaned by previously 
described methods for preparation of PM-isoK
78
 by combining 25 μL of 10 mM isoK 
(from the lab of L. Jackson Roberts) with 20 μL of 4-AMPy in 955 μL 100 mM sodium 
phosphate buffer (chelexed, pH 7.4).  At the same time, synthesis and cleaning of PM-
isoK was set up for comparison:  25 μL of 10 mM isoK with an excess of PM in quantity 
sufficient 100 mM sodium phosphate to 1.000 mL.  Both reactions shaken overnight at 55 
rpm, 37˚C.  PM-isoK and 4-AMPy-isK were cleaned on a Waters Sep-Pak C18 cartridge 
preconditioned with 10 mL methanol.  Reaction mixtures were added to the cartridge via 
syringe at a flow rate of no faster than 1 mL/min.  Samples were then washed at no more 
than 4 mL/min with 10 mL water, 10 mL methanol/water (15:85), 10 mL heptane, and 10 
mL heptane/ ethyl acetate (1:1).  Product was then eluted with 5 mL methanol/ ethyl 
acetate (1:1) at about 2 mL/min.  Eluent was dried under N2, resuspended in 400 μL of 
HPLC solvent A, and stored at <-20˚C until HPLC became available.  HPLC solvent A 
was 20 mM ammonium acetated with 0.1% v/v acetic acid.  Solvent B was 5 mM 
ammonium acetate/methanol (1:9) with 0.1% acetic acid.  A Phenomenex Luna 5u C18 
column was used to clean the products with the following gradient at 0.2 mL/min:  5 
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minutes at 100% A, ramp up to 100% B until 45 minutes, hold at 100% B until 60 
minutes, gradient back to 100% A by 65 minutes, and equilibrate with 100% A until 85 
minutes.  Runs were monitored at λ = 320 nm, 250 nm, and 220 nm.  Samples were 
collected in 0.5 dram glass vials and labeled with time, product and HPLC run number.  
Standards were then analyzed via LC-MS/MS.  Tune files were created for PM-isoK with 
a parent ion of 501 m/z, and for 4-AMPy-isoK with a parent ion of 441 m/z.  It was 
determined that using the column and gradient described above, both types of products 
eluted chiefly at 61-64 minutes.   
 The concentration of the 4-AMPy-isoK internal standard was approximated by 
UV/vis spectrometry by determining the molar absorptivity coefficient for 4-
(ethylaminomethyl)pyridine.  The constant was determined to be 2558.2 at 259 nm.  
Reactions between BH and AA were set up as described above with increasing 
concentrations of BH.  These reactions were spiked with 4-AMPy-isoK as an internal 
standard and extracted with ether as described above and taken for LC-MS/MS analysis.  
No data was acquired due to an undiscovered leak in the column while samples were 
running.   
  
35 
 
APPENDIX E 
COMPARISON OF HEME COMPOUNDS VIA IMMS 
 In order to determine if different heme species could be differentiated with ion 
mobility- mass spectrometry (IMMS), several species were compared, including hemin-
Cl, BH and μ-oxo-[Fe(III)PPIX].   For this purpose a μ-oxo-[Fe(III)PPIX] dimer was 
synthesized by methods previously described.
79
  Briefly, 1.00 g hemin chloride was 
stirred in 100 mL anhydrous methanol with 5.0 mL of 18 M H2SO4 overnight at room 
temperature.  Chloroform extracts of the mixture were washed with water, saturated 
Figure 17.  (a) BH with dihydroxybenzoic acid matrix. (b) hemin chloride with DHB 
matrix (c)  with DHB matrix. 
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sodium bicarbonate solution (7.8 g in 100 mL), and again with water.  The solution was 
then dried over anhydrous sodium sulfate and evaporated to dryness at reduced pressure.  
The product was then dissolved in benzene and chromatographed on alumina deactivated 
with 10% water.  The major band was eluted from the column with benzene:chloroform 
1:3 (v/v) and evaporated to dryness at reduced pressure.  A sample was prepared at 4.7 
mM in ethanol for IMMS analysis by Larissa Fenn, along with samples of 13.5 M hemin 
chloride and 5 mM BH.  IMMS plots of these samples are compared in Figure 17.  
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